12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AZD2820: Development discontinued

Palatin said partner AstraZeneca discontinued AZD2820. In June, AstraZeneca halted a Phase I trial after it could not exclude that a serious adverse event was linked to...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >